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ThemiR-17-92microRNA cluster is often activated in
cancer cells, but the identity of its targets remains
elusive. Using SILAC and quantitative mass spec-
trometry, we examined the effects of activation of
the miR-17-92 cluster on global protein expression
in neuroblastoma (NB) cells. Our results reveal coop-
eration between individual miR-17-92 miRNAs and
implicate miR-17-92 in multiple hallmarks of cancer,
includingproliferation andcell adhesion.Most impor-
tantly, we show that miR-17-92 is a potent inhibitor of
TGF-b signaling. By functioning both upstream and
downstream of pSMAD2, miR-17-92 activation trig-
gers downregulation of multiple key effectors along
the TGF-b signaling cascade as well as direct inhibi-
tion of TGF-b-responsive genes.
INTRODUCTION
MicroRNAs (miRNAs) belong to a regulatory class of small non-
coding RNAswith a fundamental role in numerous aspects of cell
biology, such as cell-cycle regulation, apoptosis, differentiation,
and maintaining stemness (reviewed in Bartel [2004]). Only
20–25 nucleotides (nt) in length, miRNAs function as key mole-
cules in the posttranscriptional repression of gene expression.
Upon miRNA assembly in the RNA-induced silencing complex
(RISC), binding between the miRNA seed (nt 2–7 counted from
the 50 end of the miRNA) and complementary sites in the762 Molecular Cell 40, 762–773, December 10, 2010 ª2010 Elsevier30 untranslated region (30UTR) of target mRNAs results in degra-
dation of the mRNA or inhibition of translation (reviewed in Bartel
[2009]). Based on the 30UTR site context, algorithms predict that
up to 60% of all coding genes are under the control of one or
more miRNAs (Friedman et al., 2009). However, these predic-
tions suffer from a high degree of false positives, and to date,
only a fraction of miRNA-mRNA interactions have been experi-
mentally validated.
In cancer, miRNAs function both as oncogenes or tumor
suppressors (reviewed in Calin and Croce [2006]; Esquela-Ker-
scher and Slack [2006]). Some of these miRNAs were identified
as essential components of known cancer pathways, such as
the p53-induced miR-34 family (He et al., 2007; Raver-Shapira
et al., 2007) or the c-MYC/MYCN-induced miR-17-92 cluster
(O’Donnell et al., 2005). The oncogenic miR-17-92 cluster
consists of six individual miRNAs (miR-17, miR-18a, miR-19a,
miR-19b, miR-20a, and miR-92a) located within a polycistronic
transcript on human chromosome 13. Gene duplications and
deletions eventually resulted in two miR-17-92 paralogs, the
miR-106b-25 cluster on chromosome 7 and the miR-106a-363
cluster on chromosome X. Of these clusters, miR-17-92 is the
most frequently activated one in cancer. miRNA expression
profiling studies revealed miR-17-92 overexpression, both in
hematopoietic malignancies (such as B cell lymphomas
[He et al., 2005]) and solid tumors (including breast, colon, and
lung cancer [Castellano et al., 2009; Hayashita et al., 2005; Lanza
et al., 2007]) and neuroblastoma (NB) (Mestdagh et al., 2009a).
Overexpression can result from amplification of the miR-17-92
locus (He et al., 2005) or direct miR-17-92 transactivation by
c-MYC/MYCN (Dews et al., 2010; Fontana et al., 2008; Mest-
dagh et al., 2009a; O’Donnell et al., 2005). The oncogenic nature
of miR-17-92 activation is supported by the identification ofInc.
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Figure 1. miR-17-92 Cluster Activation Is a Marker for Poor Prognosis
(A) miR-17-92 pathway activity is scored in three clinicogenetic subsets of NB tumors (data set D1, Table S1),MYCN amplified tumors (MNA),MYCN single copy
high-risk tumors (SH), andMYCN single-copy low risk tumors (SL) (whiskers: Tukey). miR-17-92 pathway activity score is significantly higher in MNA versus SH
(Mann Whitney, p < 0.05), MNA versus SL (p < 0.0001), and SH versus SL (p < 0.01).
(B) Kaplan Meier plots for overall (OS) and event free survival (EFS) based on the pathway activity score of miR-17-92, represented as quartiles. Increased activity
of miR-17-92 is proportionally correlated to both poor overall and event-free survival.
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miR-17-92 Dampens TGF-b SignalingmiR-17-92 targets with key roles in cell-cycle control and cell
death. In particular, miR-17 and miR-20a target the cyclin-
dependent kinase inhibitor CDKN1A (p21), a negative regulator
of the G1-S transition (Fontana et al., 2008), and miR-17 targets
the proapoptotic BCL2L11 (Bim) (Fontana et al., 2008). In gastric
cancer, downregulation of p21 by the miR-17 and miR-20a
paralogs miR-106b and miR-93 renders the cells insensitive to
TGF-b-induced cell-cycle arrest whereas miR-25 (a miR-92a
paralog) inhibits TGF-b-dependent apoptosis through the
repression of BCL2L11 (Petrocca et al., 2008).
Thus far, the number of identified miR-17-92 targets remains
relatively limited, thus precluding a comprehensive under-
standing of the full oncogenic potential of this miRNA cluster.
In a first step toward this goal, we examined the effects of
miR-17-92 cluster activation on the proteome of NB cancer cells.
Using quantitative mass spectrometry, we analyzed the
response of thousands of proteins upon miR-17-92 activation
in NB cells. NB is an excellent model to study the effects of
miR-17-92 activation because high-risk NB tumors are charac-
terized by increased MYCN/c-MYC activity either through
MYCN amplification or increased c-MYC expression, both re-
sulting in elevated miR-17-92 levels (Mestdagh et al., 2009a).
Our results demonstrate that miR-17-92 is implicated in multiple
hallmarks of the tumorigenic program, including proliferation
and cell adhesion. Most importantly, we dissect the role of
miR-17-92 as a potent inhibitor of TGF-b-signaling acting on
multiple levels along the signaling cascade.
RESULTS
miR-17-92 Cluster Activation Is a Marker for Poor
Survival
In NB, miR-17-92 expression is activated through direct MYCN/
c-MYC promoter binding (Fontana et al., 2008; Mestdagh et al.,
2009b). We quantified miR-17-92 expression on a cohort of 95
primary untreated NB tumor samples (data set D1, Table S1;MolecGEO accession number GSE21713) (Mestdagh et al., 2009a).
The activation of the entire miR-17-92 cluster was evaluated by
means of a pathway activity score (Fredlund et al., 2008; Mest-
dagh et al., 2009a). NB tumors were divided into three cohorts,
MYCN single copy low-risk tumors (SL), MYCN single copy
high-risk tumors (SH), and MYCN amplified tumors (MNA). The
miR-17-92 pathway activity was highest in the MNA tumors,
followed by the SH tumors and the SL tumors (Figure 1A). Each
individual miRNA is upregulated in the MNA samples suggesting
that the entiremiR-17-92 cluster, rather than a subset ofmiRNAs,
is of potential relevance (Mann Whitney, p < 0.05) (Figure S1A).
We next evaluated miR-17-92 pathway activation with respect
to NB patient survival. Kaplan-Meier analysis demonstrated
that miR-17-92 activity was proportional to overall and event-
free survival (log rank, p < 0.001), underscoring the importance
of miR-17-92 activation in NB tumor biology (Figure 1B). Except
for miR-19b, expression of the other miRNAs within the
miR-17-92 cluster showed similar correlations (Figure S1B).
Impact of miR-17-92 Activation on Protein Output
To study the regulatory effects of miR-17-92 activation, quantita-
tive mass spectrometry was applied to measure protein
response in a cellular model (SHEP-TR-miR-17-92) with tetracy-
cline-inducible miR-17-92 expression (Mestdagh et al., 2009a).
This approach provides the most relevant readout as it directly
measures the impact of a miRNA on protein output (Baek
et al., 2008; Selbach et al., 2008). Average miR-17-92 induction
upon tetracycline treatment was in the range of miR-17-92 fold
changes between MNA and SL tumors (Figure S2A) (data not
shown). Profiling of 430 miRNAs revealed no significant effects
on global miRNA expression suggesting that miR-17-92 induc-
tion does not affect the processing of other miRNAs (data not
shown). SHEP-TR-miR-17-92 cells were differentially labeled
using SILAC (stable isotope labeling with amino acids in cell
culture) (Ong et al., 2002) and then either treatedwith tetracycline
for 72 hr or left untreated, followed by methionine COFRADICular Cell 40, 762–773, December 10, 2010 ª2010 Elsevier Inc. 763
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Figure 2. Analysis of Global Protein Expression upon miR-17-92 Activation
(A) Tetracycline treated (+TET) and untreated (TET) SHEP-TR-miR-17-92 cells were metabolically labeled using SILAC. Methionine-containing peptides were
isolated using COFRADIC technology and subsequently analyzed using LC-MS/MS.
(B) Representative LC-MS/MS spectra for an upregulated protein (NNMT), unchanged protein (RRM2), and downregulated protein (SERPINE1).
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miR-17-92 Dampens TGF-b Signalingisolation of methionyl peptides (Gevaert et al., 2002) and identi-
fication of these peptides by LC-MS/MS (Figure 2A). Only
proteins that were quantified by at least two different peptides
over two different proteome analyses (n = 3249) were selected
for further analysis (Colaert et al., 2010). Most proteins were in
fact quantified by more than two peptides (Figure S3B). Differen-
tial protein expression was determined as the average protein
ratio of the differentially labeled fractions across the biological
replicates (Table S2; Figures 2B and S3C). Based on a fold-
change expression cutoff of 0.5 log2 units (see Supplemental
Information for cutoff definition), 144 proteins were downregu-
lated upon miR-17-92 activation.
To assess whether the measured protein response reflects
regulatory miR-17-92 effects, we performed an unbiased search
for all possible 7-mermotifs (n =16,384) in the 30UTRof thedown-
regulated proteins (15th percentile) and compared these to motif
occurrence in the 30UTR of the remaining proteins. We found
seven motifs to be overrepresented in the 30UTR of the downre-
gulated proteins, with the five most significant motifs belonging
to the miR-17-92 miRNAs: miR-17, miR-19a, miR-19b,
miR-20a, andmiR-92a (Fisher Exact, p < 0.05, Bonferonimultiple
testing correction) (Figure 3A). Strikingly, there was no enrich-
ment for miR-18a seeds, suggesting that miR-18a does not
substantially contribute to protein repression upon miR-17-92
activation. Analyses using the 20th percentile gave similar results764 Molecular Cell 40, 762–773, December 10, 2010 ª2010 Elsevier(data not shown). Analyses for the 50UTR and coding sequence
(CDS) did not reveal significant enrichments for miR-17-92
miRNA seed sequences. However, we did observe an enrich-
ment for the 7-mer-m8 seed of miR-17* in the CDS of the
downregulated proteins, suggesting that miR-17*-mediated
protein repression might depend on CDS binding.
To evaluate miR-17-92 seed efficiency with respect to protein
repression, we plotted the cumulative distribution of protein fold
changes for proteins with at least one miR-17-92 30UTR 6-mer,
7-mer-A1, 7-mer-m8, or 8-mer seed and compared these to
proteins without miR-17-92 seeds (Figure 3B). As expected,
protein repression was highest in the presence of an 8-mer
seed (Kolmogorov-Smirnov, p = 2.20 3 1016) followed by
7-mer-m8 (p = 1.11 3 106), 7-mer-A1 (p = 0.00011) and 6-mer
seeds (p = 0.0027). When evaluating each miR-17-92 miRNA
separately, we observed similar results for miR-17/miR-20a,
miR-19a/miR-19b, and miR-92a (miR-17/mir-20a and miR-19a/
miR-19b were analyzed together as they share identical seeds)
(Figure 3C). For miR-18a, the relation between seed occurrence
and protein fold changewas less pronounced, further supporting
our observation that the contribution of miR-18a to miR-17-92-
mediated protein repression is limited.
The fraction of proteins containing at least onemiR-17-92 7-8-
mer seed was highest for proteins that were downregulated at
least 2-fold (82%) and decreased to background levels (45%)Inc.
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Figure 3. miR-17-92 Activation Induces Widespread Repression of Targeted Proteins
(A) Overview of all significantly enriched heptamermotifs in the 30UTR of transcripts from repressed proteins. The top five significantly enrichedmotifs correspond
to miR-17-92 target sites. One motif corresponds to the 7-mer-m8 seed of the miR-302/miR-372 family, which differs in only one base with the 7-mer-m8 seed of
miR-17/miR-20a. The last motif did not correspond to any known miRNA nor did it show any overlap with miR-17-92 seeds.
(B) The cumulative distribution of protein fold changes upon miR-17-92 activation, calculated for five different protein subsets: proteins with at least one miR-17-
92 8-mer site (red), 7-mer-m8 site (blue), 7-mer-A1 site (yellow), 6-mer site (green), and no site (black).
(C) Identical analysis as in (B) but for each individual miRNA from the miR-17-92 cluster. The miR-17/miR-20a and the miR-19a/miR-19b were analyzed together
as they share identical seeds.
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miR-17-92 Dampens TGF-b Signalingfor unchanged proteins (Figure S3A). Robust protein repression
was also characterized by the presence of multiple miR-17-92
30UTR sites per protein (Figure S3B), suggesting that individual
miR-17-92 miRNAs cooperate to achieve target repression.
This correlation was only observed for 30UTR sites and not for
50UTR or CDS sites (Figures S3C and S3D). To further evaluate
miRNA cooperation, we analyzed co-occurrence of individual
miR-17-92 sites in the 30UTR of downregulated proteins and
compared this to co-occurrence in the 30UTR of upregulated
proteins (used as a reference control set). We identified signifi-
cant co-occurrence for miR-17/miR-20a sites and miR-19a/
miR-19b sites confirming cooperation between individual
miRNAs (Figure S3E). miR-18a sites almost never occurred in
the absence of other miR-17-92 sites (8.33%) and were signifi-
cantly associated with miR-17/miR-20a sites (Figure S3E).
miR-17-92 Affects Multiple Cancer Pathways
To gain insight into the pathways affected by oncogenic
miR-17-92 activation, we performed gene set enrichment anal-
ysis (GSEA) (Subramanian et al., 2005) using all measured
proteins, ranked according to their fold change. Thirty-six
gene sets were significantly enriched in the positive phenotypeMolec(i.e., downregulated proteins) while nine were enriched in the
negative phenotype (i.e., upregulated proteins). Of the latter,
six were related to increased metabolic activity of the mito-
chondrial oxidative phosphorylation energy production
pathway (Figure S4). In NB, miR-17-92 expression is activated
by MYCN/c-MYC transcription factors that have been shown to
regulate genes involved in the biogenesis of mitochondria and
metabolism (Zhang et al., 2007). Our results now provide
evidence that this, at least in part, is mediated through
miR-17-92 activation.
The contribution of each individual miRNA to the significant
gene lists in the positive phenotype was calculated and visual-
ized as a heatmap (Figure 4A). Among the gene lists enriched
in the positive phenotype, which reflect direct miR-17-92-regu-
lated pathways, we identified multiple cancer-related processes
such as cell proliferation, cell adhesion, TGF-b signaling,
estrogen-signaling, and RAS signaling (Figure 4A). Hierarchical
clustering reveals a close association between miR-17/
miR-20a- and miR-19a/miR-19b-regulated pathways, reflecting
the previously observed co-occurrence of these sites. Again,
miR-18a clusters further away from the remaining miR-17-92
miRNAs and is characterized by weak gene list associations.ular Cell 40, 762–773, December 10, 2010 ª2010 Elsevier Inc. 765
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Figure 4. miR-17-92 Activation Regulates Multiple Cancer Pathways
(A) Heatmap of significant miRNA-pathway associations, identified through gene set enrichment analysis. The intensity of the association is based on the fraction
of genes with at least one 7-mer or 8-mer 30UTR site.
(B) Normalized cell index (mean ± standard deviation) as a measure for proliferation of tetracycline treated (+TET) and untreated (TET) SHEP-TR-miR-17-92
cells. Treatment was initiated 20 hr post seeding.
(C) Evaluation of the cell-cell adhesion of tetracycline treated and untreated SHEP-TR-miR-17-92 cells. Measurements of the relative cluster area for three inde-
pendent experiments using ImageJ are displayed as bar plots. UponmiR-17-92 activation, the area of the clusters dropped by >50% resulting in more but smaller
aggregates.
(D) Representative analyses of bioluminescence imaging (BLI) of luciferase positive SHEP-TR-miR-17-92 and SHEP-TR cells injected etherotopically and subcu-
taneously in the right and left flank of nude athymic mice. Bar scale color indicates the number of photons/s measured by IVIS 3D imaging instrumentation. SHEP
miR17-92 cells in vivo are still alive after 21 days post cell subcutaneous implantation.
(E) Bioluminescence imaging (BLI) of luciferase positive SHEP-TR-miR-17-92 and SHEP-TR cells injected etherotopically and subcutaneously in the right and left
flank of nude athymicmice. Luciferase signals weremeasured at 0, 7, 14, and 21 days postengraftment and are shown as themean ± SEMof fivemice. Significant
differences between SHEP-TR and SHEP-TR-miR-17-92 cells are indicated by * (Student t test, p < 0.05) and ** (Student t test, p < 0.01).
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miR-17-92 Dampens TGF-b SignalingIn NB, the oncogenic nature of miR-17-92 has been ascribed
to its ability to promote cell proliferation through the regulation
of CDKN1A and BCL2L11 (Fontana et al., 2008). GSEA results
indicate that miR-17-92 has a much broader influence and
targets different oncogenic pathways. As a proof of concept,
we tried to validate the association with increased proliferation766 Molecular Cell 40, 762–773, December 10, 2010 ª2010 Elsevierand decreased cell adhesion in the SHEP-TR-miR-17-92
cells. Cell proliferation was evaluated in real-time using the
xCELLigence system. Upon miR-17-92 activation, proliferation
of SHEP-TR-miR-17-92 cells increased (Figure 4B) and intercel-
lular cell adhesion significantly decreased (Figure 4C). To eval-
uate the effect of miR-17-92 activation in vivo we performedInc.
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Figure 5. miR-17-92 Activation Represses the TGF-b Pathway
(A) Gene set enrichment analysis plots for three different TGF-b gene sets showing significant enrichment among the miR-17-92 repressed proteins.
(B) TGF-b pathway activity score in MYCN amplified NB tumors (MNA) and MYCN single-copy NB tumors (MNSC) (data set D2, Table S1). MNA tumors show
significantly lower TGF-b pathway activity (Mann Whitney, p < 0.001) (whiskers: Tukey).
(C) KaplanMeier plot for event free survival (EFS) based on the TGF-b pathway activity score, represented as quartiles (dataset D2, Table S1). Increased activity of
miR-17-92 is proportionally correlated to event-free survival.
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miR-17-92 Dampens TGF-b Signalingetherotopic injection of SHEP-TR-miR-17-92 and SHEP-TR
(control) cells in the right and left flanking site, respectively, of
atymic nude mice that were given tetracyclin and visualized
tumor cells using bioluminescence imaging. For SHEP-TR cells,
the luciferase signal dropped to background levels after 7 days
of engraftment, which is in line with previous findings demon-
starting that SHEP cells are not tumorigenic in vivo (Schweigerer
et al., 1990) (Figures 4D and 4E). In contrast, SHEP-TR-miR-17-
92 cells persisted much longer and showed statistically higer
luciferase signals at 7, 14, and 21 days, indicating that, although
tumorigenesis decreases, miR-17-92 activation significantly
prolongs the engraftment of SHEP cells, probably through
increased proliferation and decreased apoptosis, activities
previously ascribed to miR-17-92 overexpression (Fontana
et al., 2008). Together, these results confirm the relation between
miR-17-92 activation and cell proliferation and reveal a role for
miR-17-92 in the regulation of cell adhesion, hereby confirming
the GSEA results.
miR-17-92 Impairs TGF-b Activity
GSEA analysis identified three TGF-b-responsive gene sets
(Padua et al., 2008; Verrecchia et al., 2001) among the proteins
downregulated upon miR-17-92 activation in the SHEP-TR-
miR-17-92 cells (Figure 5A). To exclude the possibility thatMolecrepression of TGF-b-responsive genes is an artifact of miRNA
overexpression, we analyzed eight published protein expression
data sets of miRNA overexpression (Baek et al., 2008; Selbach
et al., 2008) using GSEA. None of the TGF-b gene lists were
significantly enriched in any of the data sets, suggesting the
observed effect to be related to miR-17-92. For a subset of the
TGF-b-responsive genes, the measured protein repression
was confirmed on the mRNA level using RT-qPCR (Figure S5).
We next evaluated this TGF-b signature in NB tumor samples
using the pathway activity score of all genes that significantly
contributed to the GSEA results (n = 21). For this purpose, we
used the larger Oberthuer data set (Oberthuer et al., 2006)
(data set D2, Table S1) to increase the power of our analysis.
TGF-b pathway activity was significantly downregulated in
MNA NB tumors that are characterized by high miR-17-92
expression (Mann Whitney, p < 0.001) (Figure 5B), and showed
a negative correlation to MYC pathway activity (Spearman’s
Rank p < 0.01, rho = 0.460). In addition, Kaplan-Meier survival
analysis indicates that tumors with low TGF-b pathway activity
are characterized by poor event-free survival (log-rank, p <
0.0001) (Figure 5C). To further substantiate the inverse relation
between TGF-b target gene expression and miR-17-92 expres-
sion, we performed an expression correlation analysis in a subset
of 40 of the 95 NB tumors for which also mRNA expression wasular Cell 40, 762–773, December 10, 2010 ª2010 Elsevier Inc. 767
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(A and B) Immunohistochemical detection of phos-
phorylated SMAD2 protein (pSMAD2) in tetracy-
cline treated (+TET) and untreated (TET)
SHEP-TR-miR-17-92 cells. The cell intensity
measurement (mean ± SEM) reveals a significant
decrease in pSMAD2 levels in tetracycline treated
cells (Mann Whitney, p < 0.0001).
(C) Western blot analysis indicates a strong
decrease (2.3-fold) in pSMAD2 levels upon
miR-17-92 induction (+TET).
(D) The relative luciferase activity of a pSMAD2
reporter construct (mean ± SEM). Activation of
miR-17-92 expression through tetracycline treat-
ment (+TET) results in a significant (*) decrease in
reporter activity after stimulation of the TGF-b
pathway with TGF-b1 (TGF-b ligand). TGF-b-inhib-
itor treatment completely abrogates the reporter
activity.
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miR-17-92 Dampens TGF-b Signalingavailable (data set D3, Table S1) (Mestdagh et al., 2009a). Hier-
archical clustering of the correlation coefficients revealed that,
indeed, miR-17-92 expression inversely correlates to TGF-b
target gene expression (Figure S6A). These results confirm that
TGF-b signaling is downregulated in aggressive NB tumors
with high miR-17-92 expression and underscore the potential
importance of TGF-b activity in NB tumor biology.
We next evaluated which components of the TGF-b signaling
cascade are controlled by miR-17-92 miRNAs. One important
effector of active TGF-b signaling is phosphorylated SMAD2
protein (pSMAD2) that translocates to the nucleus to induce
gene transcription. Upon tetracycline treatment of SHEP-TR-
miR-17-92 cells, we observed a significant decrease in nuclear
pSMAD2 levels (Mann Whitney, p < 0.0001) (Figures 6A–6C). A
similar decrease was observed for pSMAD3 levels (data not
shown). When SHEP-TR-miR-17-92 cells were transfected
with a plasmid containing a SMAD-regulated luciferase reporter
([CAGA]12-Luc) and treated with TGF-b1, a strong activation of
the reporter gene was observed (Figure 6D). However, when
miR-17-92 expression was activated through tetracycline treat-
ment, reporter gene activation was substantially attenuated
(Mann Whitney, p < 0.001) (Figure 6D). When the SHEP-TR-
miR-17-92 cells were cultured in the presence of the potent
TGFBR1 inhibitor SB431542 (Laping et al., 2002), the SMAD
reporter gene activity was completely abrogated (Figure 6D).
These results suggest that miR-17-92 activation impairs the
TGF-b signaling cascade by acting upstream of pSMAD2.
miR-17-92 AffectsMultiple Levels of the TGF-bPathway
As decreased pSMAD2 levels are either caused by reduced
receptor activity or reduced SMAD2 expression, we quantified
TGFBR2 and SMAD2 mRNA expression in the SHEP-TR-
miR-17-92 cells. Both TGFBR2 and SMAD2 expression levels768 Molecular Cell 40, 762–773, December 10, 2010 ª2010 Elsevier Inc.decreased by at least 1.5-fold upon
miR-17-92 activation (Figure 7A).
SMAD4, the binding partner of pSMAD2,
also displayed a decrease in expression
upon miR-17-92 activation (Figure 7A).This negative correlation with miR-17-92 expression could be
confirmed in primary NB tumor samples for SMAD2 and TGFBR2
(Spearman’s Rank, p < 0.01) (Figure 7B), suggesting that miR-17-
92 regulates their expression. Indeed, both genes contain
miR-17-92 binding sites in their 30UTR and a direct interaction
between TGFBR2 and miR-20a has been established (Volinia
et al., 2006). This miR-17-92 mediated silencing of TGFBR2
ultimately results in decreased pSMAD2 levels and decreased
transcription of the TGF-b-target genes. In total, we identified 13
TGF-b-target genes to be downregulated on the protein level
with a log2 fold change < 0.5 (7 out of 20 proteins in the
PADUA_TGFB_UP gene set, 3 out of 16 proteins from
the TGFB_EARLY_UP gene set, and 7 out of 28 proteins from
the TGFB_ALL_UP gene set) (Table S3). As ten of these genes
harbor miR-17-92 binding sites in their 30UTR (Table S3), we
wondered whether they might also be targeted directly by
miR-17-92. To exclude the effects ofmiR-17-92 directed inactiva-
tion of TGF-b signaling on the expression of TGF-b-responsive
genes, we first treated SHEP-TR-miR-17-92 cells for 4 hr with
the TGFBR1 inhibitor SB431542, which completely abrogates
TGF-b signaling (Figure 6C). Cells were subsequently treated
with tetracycline to activate miR-17-92 expression and harvested
at 24 hr and 48 hr after tetracycline treatment. From the six genes
that were evaluated, three (CDKN1A, ITGA4, and SERPINE1)
were downregulated after 24 hr of TGF-b-inhibitor treatment
(t test, p < 0.05), confirming that they are regulated by TGF-b (Fig-
ure 7C). The remaining three genes (FNDC3B, ICAM1, and
THBS1) did not show any differential expression after 24 hr;
however, FNDC3B and THBS1 did respond to TGF-b-inhibitor
treatment after 48 hr (data not shown). This suggests that, in
NB, these are either not or indirectly responsive to TGF-b signaling
(Figure 7D). Upon miR-17-92 activation, the TGF-b-responsive
genes were further downregulated (t test, p < 0.001) (Figure 7C),
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expression of these genes, independent of its ability to inactivate
TGF-b signaling. As expected, the genes that were not responsive
to TGF-b inhibition did show decreased expression uponmiR-17-
92 activation (t test, p < 0.001) (Figure 7D).
To investigate which specific miRNAs contribute to the repres-
sion of the TGF-b-pathway, we overexpressed each miRNA from
the miR-17-92 cluster separately and measured the expression
of TGF-b-pathway components and target genes. Interestingly,
we found that each miRNA contributes to the repression of one
ormore genes from the TGF-b pathway, suggesting that the entire
miR-17-92 cluster, rather than a subset of miRNAs, mediates the
repression of TGF-b signaling in NB cells (Figure S6B). Downregu-
lation (log2 fold change < 0.5) upon miRNA transfectection was
almost exclusively observed for those genes harboring a 30UTR
seed site for the respective miRNA (Fisher Exact, p < 0.001).
We next evaluated whether the miR-17-92-induced downre-
gulation of TGF-b-pathway components is caused by direct
binding between miR-17-92 miRNAs and miR-17-92 seed sites
in the 30UTR of TGFBR2, SMAD2, and SMAD4. To this purpose,
DLD1DICERhypo cells were transfected with 30UTR luciferase
reporter plasmids in combinationwith a pre-miR negative control
or amiR-17-92 pre-miR for which one ormultiple seed sites were
present in the 30UTR of the respective genes. We identified
a direct interaction between TGFBR2 and miR-17/20, SMAD2
and miR-18a, and SMAD4 and miR-18a, as evidenced by the
significant decrease in luciferase activity compared to the pre-
miR negative control (t test, p < 0.01, Figure 7E). Other putative
miR-17-92 sites in the 30UTR of TGFBR2 (miR-19a/miR-19b),
SMAD2 (miR-19a/miR-19b, miR-92a), and SMAD4 (miR-19a/
miR-19b) did not affect luciferase signals (data not shown).
Mutagenesis of the active miRNA seed sites resulted in a signifi-
cant rescue of the luciferase signal (t test, p < 0.01), suggesting
that the observed effects depend on the presence of the 30UTR
seed site. These results confirm TGFBR2 as a direct miR-17-92
target gene and identify two additional TGF-b-pathway compo-
nents, SMAD2 and SMAD4, as miR-17-92 target genes.
To assess the importance of TGF-b-pathway inhibition in the
proliferation phenotype observed upon miR-17-92 activation,
we overexpressed SMAD2 and SMAD4 in the presence of acti-
vated miR-17-92. SMAD2/SMAD4 overexpression resulted in
a 25% decrease in cell growth (t test, p < 0.05), indicating that
miR-17-92 accelerated proliferation is, at least in part, depend-
ing on the downregulation of the TGF-b pathway. The relatively
modest decrease in cell growth is probably explained by the
fact that miR-17-92 directly regulates TGF-b target genes in
a SMAD2/SMAD4 independent manner.
In conclusion, our data demonstrate that miR-17-92 activation
triggers a targeted clampdown of TGF-b signaling by acting on
multiple key effectors along the signaling cascade, as well as
through the direct inhibition of TGF-b-responsive genes, hereby
repressing the cytostatic effects of active TGF-b signaling
(Figure S7).
DISCUSSION
Transcriptional activation of the miR-17-92 miRNA cluster by
MYC/MYCN transcription factors occurs in multiple tumor enti-Molecties, including NB (Hayashita et al., 2005; Mestdagh et al.,
2009a; O’Donnell et al., 2005). Although the oncogenic nature
of miR-17-92 activation is well established, the underlying
targets and signaling cascades that are deregulated remain
largely elusive. In addition, studies aimed at determining
miR-17-92 targets have focused on individual members of the
cluster, despite the observation that the entire cluster is acti-
vated (Mestdagh et al., 2009b; O’Donnell et al., 2005). Here,
we have used an unbiased proteomics approach to identify
miR-17-92 targeted pathways in a NB tumormodel. Direct quan-
titative measurement of protein expression is preferred over the
more straightforward mRNA profiling as a high-throughput
method for miRNA target identification (Baek et al., 2008; Sel-
bach et al., 2008).
Computational analysis of miR-17-92 seeds in the 30UTR of
transcripts from proteins supported the expected enrichment
of direct miR-17-92 targets within the list of downregulated
proteins detected usingmass spectrometry.Moreover, a propor-
tional relationship between seed frequency and fold downregu-
lation was noted. This relationship not only holds for multiple
seeds from an individual miR-17-92 miRNA but also for multiple
seeds from different miR-17-92 miRNAs, suggesting coopera-
tion between individual miRNAs from the cluster toward target
protein repression. miR-17-92 miRNAs have indeed been shown
to function in a cooperative and additivemanner among others in
the regulation of PTEN by miR-17 and miR-19 (Xiao et al., 2008).
Our results further indicate that miR-19a/miR-19b and miR-17/
miR-20a sites significantly co-occur in the 30UTR of transcripts
from several downregulated proteins. As these co-occurring
sites were not observed for every possible combination of indi-
vidual miR-17-92 miRNAs, we hypothesize that in NB, the
miRNA components of the miR-17-92 cluster can regulate target
expression either individually or in certain combinations with
additive effects. However, miR-17-92 function might be highly
context and cell-type specific as miR-19 was shown to be
both necessary and sufficient to promoteMYC-induced lympho-
magenesis in the Em-myc mouse B cell lymphoma model (Olive
et al., 2009).
While the fraction of downregulated proteins was enriched for
seeds of miR-17/miR-20a, miR-19a/miR-19b, and miR-92a,
enrichment for the miR-18a seed was not detected. Strikingly,
miR-18a seeds rarely occur as the only seed(s) in the 30UTR of
a downregulated target and showed little or no correlation to
protein fold change. Although this suggests that miR-18a is not
substantially contributing to target deregulation, it does not imply
that miR-18a lacks functionality, as miR-18a has been shown to
regulate important cancer genes such as CTGF in colon cancer
and estrogen receptor-a (ESR1) in NB (Dews et al., 2006; Love´n
et al., 2010). Interestingly, we found miR-18a to regulate both
SMAD2 and SMAD4, two key components of the TGF-b-signaling
cascade, suggesting that miR-18a substantially contributes to
pathway deregulation by regulating a selected set of target genes.
When all cluster components were combined, we identified
a large number of targeted proteins belonging to diverse cancer-
related pathways. Notably, estrogen receptor signaling was also
among the targeted pathways. The fact that we identified such
a wide variety of functions in NB cells suggests that miR-17-92
pleiotropy is not only related to different targets in different cellular Cell 40, 762–773, December 10, 2010 ª2010 Elsevier Inc. 769
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Figure 7. miR-17-92 Targets Multiple Components of the TGF-b Pathway
(A) The relative mRNA expression of TGF-b-responsive genes in tetracycline treated (+TET) and untreated SHEP-TR-miR-17-92 cells (+TET) (mean ± SEM).
(B) Significant negative correlation between TGFBR2 mRNA expression and miR-17-92 expression and SMAD2 mRNA expression and miR-17-92 expression in
primary NB tumors. Spearman’s rank rho-values and p values are listed.
(C and D) The relative mRNA expression (mean ± SEM) of a representative set of genes responsive to TGF-b (C) and genes not or (indirectly) responsive to TGF-b
(D) in SHEP-TR-miR-17-92 cells that were either untreated, treated with TGF-b inhibitor, or treated with TGF-b inhibitor followed by miR-17-92 activation with
tetracycline (TET) for 24 hr. In (C), genes respond to TGF-b-inhibitor treatment (t test, p < 0.05, indicated by *) and show an additional decrease in expression
upon combined TGF-b-inhibitor treatment and miR-17-92 activation (t test, p < 0.001, indicated by *). In (D), genes only respond to mR-17-92 treatment
(t test, p < 0.001, indicated by **).
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miR-17-92 Dampens TGF-b Signalingtypes but alsooccurswithin cell types. Themolecular basis for this
observation likely lieswithin themultiplecomponentsof thecluster
and the complex interplay between them.
mir-17-92-directed regulation of the TGF-b-responsive genes
CDKN1A and BCL2L11 in NB cells has been described previ-
ously (Fontana et al., 2008). In gastric cancer, members of the
miR-106b-25 cluster have also been shown to target CDKN1A
and BCL2L11 (Petrocca et al., 2008). Here we comprehensively
demonstrate thatmiR-17-92dampensTGF-b signaling in amulti-
faceted way by acting both upstream and downstream of
pSMAD2/SMAD4, further underscoring its ability to regulate
multiple components of the same pathway. This ability to simul-
taneously target the components of the signaling cascade, as
well as the downstream effectors through multiple miRNAs,
allows for tight control of the TGF-b-transcriptional program.
Moreover, it offers the cells enormous flexibility and plasticity
for regulation of different subsets of TGF-b target genes. In NB,
enhanced TGF-b signaling, through increased TGFBR2 expres-
sion, results in reduced cell growth in vitro and disables the ability
of the cells to form tumors in vivo (Turco et al., 2000). Instead,
cells assume a terminally differentiated neuronal phenotype
and display increased expression of axonal growth-associated
protein (GAP43) and neurofilaments (Turco et al., 2000). Treat-
ment of NB cells with TGF-b1 induces a similar phenotype
(Scarpa et al., 1996). In addition, retinoic acid (RA) induces
differentiation of NB cells, known to downregulate MYCN,
accompanied by the increased expression of TGF-b1, TGFBR1,
TGFBR2, andTGFBR3, resulting in the induction of a negative au-
tocrine TGF-b1 growth regulatory loop (Cohen et al., 1995). We
have shown that aggressive NB tumors evade the cytostatic
TGF-b pathway through miR-17-92 directed targeting of key
componentsof thepathwayaswell asdownstreameffectors.Re-
activation of TGF-b signaling through miR-17-92 inhibition could
beapromising therapeutic approach, as it would not only result in
reactivation of TGFBR2 expression but also relieve the direct
miR-17-92-mediated repression of TGF-b-responsive genes.
EXPERIMENTAL PROCEDURES
Cell Culture
SHEP-TR-miR-17-92 cells (Mestdagh et al., 2009a) were cultured in RPMI
(Invitrogen) supplemented with 10% fetal calf serum unless stated otherwise.
SHEP-TR-miR-17-92cellswere treatedwith2mg/ml tetracycline (Sigma-Aldrich)
to inducemiR-17-92expression (FigureS2A). TGF-b1 (PeproTech) and TGFBR1
inhibitor (SB431542, Sigma-Aldrich) were used at a concentration of 0.25 ng/ml
and 2 mM, respectively, unless stated otherwise.
COFRADIC Analysis
SHEP-TR-miR-17-92 cells were metabolically labeled by growing them in
DMEM medium supplemented with dialyzed fetal calf serum and with either
heavy lysine and arginine (both 13C6) or with natural, light lysine and arginine
(12C6). This stable isotope labeling (SILAC [Ong et al., 2002]) ensures that
following trypsin digestion, all generated peptides can be quantified by
mass spectrometry (MS, see Supplemental Information). Mass spectrometry
data for the forward en reverse experiment are available in Tables S4 and S5(E) Relative 30UTR luciferase reporter activity for TGFBR2, SMAD2, and SMAD4,m
site for the active miRNA were introduced in DLD1DICERhypo cells in combination
is decreased significantly in the presence of the active miRNA (*) (t test, p < 0.01) a
(t test, p < 0.01).
Molecand in the PRIDE database (http://www.ebi.ac.uk/pride; Accession number
14860).
mRNA and miRNA Expression Quantification
See Supplemental Information for details on mRNA and miRNA quantification
and data normalization. miRNA expression data are available in rdml format
(Document S2) (Lefever et al., 2009).
Immunohistochemistry and Western Blot
Briefly, SHEP-TR-miR-17-92 cells, tetracycline treated or untreated, were
stimulated with TGF-b1 for 4 hr. pSMAD2 activity was evaluated by immuno-
chemistry on cytopreparations or by western blot. See Supplemental Informa-
tion for detailed experimental procedures.
Cell Adhesion and Proliferation Assays
Details on cell adhesion and proliferation assays are described in the Supple-
mental Information.
Xenografts
SHEP-TR-miR-17-92 and SHEP-TR (control) cells were transfected with
a luciferase expressing mammalian vector. Etherotopic xenografts were es-
tablished in atymic nude mice (n = 5) by injection of 106 SHEP-TR cells subcu-
taneosly in the left flanking site and 106 SHEP-TR-miR-17-92 cells in the right
flanking site of each individual animal. See Supplemental Information for
detailed experimental procedures.
CAGA-Luciferase Reporter Assay
For luciferase experiments, tetracycline or control treated SHEP-TR-miR-17-
92 cells were transfected with the (CAGA)12-Luc luciferase reporter vector
and assayed for luciferase and renilla activity. See Supplemental Information
for detailed experimental procedures.
30UTR Reporter Assay
DLD1Dicerhypo cells were seeded in DMEM (Invitrogen) supplemented with
fetal calf serum (10%) at a density of 10,000 cells per well in an opaque
96-well plate. Twenty-four hours after seeding, using DharmaFECT Duo (Dhar-
macon), cells were cotransfected, either with a combination of a 30UTR con-
taining pGL4.11[luc2p] vector (Switchgear Genomics), a pRL-TK vector
(Promega) for normalization, and a miR-17-92 pre-miR (Ambion) (10 nM) or
with a combination of a psi-check2 vector (Promega) containing only part of
the 30UTR and amiR-17-92 pre-miR. Forty-eight hours after transfection, lucif-
erase reporter gene activity was measured using the Dual-Glo Luciferase
Assay System (Promega) and a FLUOstar OPTIMA microplate reader (BMG
LABTECH). See Supplemental Information for details on plasmid construction
and miRNA binding site mutation.
Statistics
See Supplemental Information for details on all statistical procedures and gene
set enrichment analysis.
ACCESSION NUMBERS
The Gene Expression Omnibus accession number for the mRNA expression
data reported in this paper is GSE21713. The PRIDE accession number for
the protein expression data reported in this paper is 14860.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, five tables, Supplemental
Experimental Procedures, Supplemental References, and an RDML file foreasured in DLD1DICERhypo cells (mean ± SEM). Plasmidswith awild-type seed
with a pre-miR negative control (NC) or miR-17-92 pre-miR. Luciferase activity
nd increases significantly when the seed for the active miRNA is mutated (MUT)
ular Cell 40, 762–773, December 10, 2010 ª2010 Elsevier Inc. 771
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molcel.2010.11.038.
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